Contact
Group lead
Dr Ernesto Yague
+44 (0)20 7594 2802
ernesto.yague@imperial.ac.uk
Related themes
Disease areas
What we do
We investigate how cancer cells develop resistance to treatment and make it ineffective.
Why it is important
Chemotherapy is widely used in cancer treatment, but unfortunately a high proportion of patients develop resistance and the treatment is no longer effective. In many cases this has fatal consequences.
How it can benefit patients
Understanding the mechanisms by which cancer cells become resistant to therapy may help us to determine which patients may or may not benefit from certain therapies as well as in the development of novel therapeutic strategies.
Summary of current research
- Control of drug resistance by microRNAs
- miR-106b~25 cluster and EP300 as regulators of E-cadherin
- EP300 in metaplastic breast cancer
- miR-218 as regulator of apoptosis (via surviving)
- miR-205 as regulator of FGF2
Connections
Funders
Related Centres and Facilities
For patients
Collaborators
- Dr Yunhui Hu - China Tianjin Breast Cancer Prevention, Treatment and Research Center
- Prof. Parmjit Jat - UCL
PhD students
Current PhD students:
- Roman Jugov
- Allison Hills
Our researchers
Dr Ernesto Yague
Dr Ernesto Yague
Non-Clinical Lecturer in Cancer Cell Biology
